When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report
Unleashing adaptive immunity via immune checkpoint inhibitors (ICPIs) in many cancer types led to durable antitumor responses and prolonged survivals and also added some new immune-related adverse events (irAEs) to the ‘old-fashioned’ safety profile of chemotherapy. Among bowel and endocrine irAEs,...
Saved in:
| Main Authors: | Paolo Antonio Ascierto, Amalia Anastasopoulou, Helen Gogas, Evangelos Cholongitas, Panagiotis Diamantopoulos, Aikaterini Gkoufa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001322.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy
by: John Haanen, et al.
Published: (2020-10-01) -
Exploring the Dynamics of Immune Checkpoint Inhibitor‐Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis
by: Panagiotis T. Diamantopoulos, et al.
Published: (2025-04-01) -
Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
by: G. Lyrarakis, et al.
Published: (2024-01-01) -
When is enough, enough? And what should the criminologist say?
by: Christie Nils
Published: (2003-01-01) -
When Acid Suppression Is Not Enough: Endoscopy and GERD
by: Alan BR Thomson
Published: (2002-01-01)